COVID-19 vaccines: neutralizing antibodies and the alum advantage
Peter J Hotez, David B Corry, Ulrich Strych, Maria Elena Bottazzi, Peter J Hotez, David B Corry, Ulrich Strych, Maria Elena Bottazzi
Abstract
Achieving high levels of neutralizing antibodies to the spike protein of SARS-CoV-2 in a safe manner is likely to be crucial for an effective vaccine. Here, we propose that aluminium-based adjuvants might hold the key to this.
Conflict of interest statement
P.J.H. and M.E.B. are investigators leading the development of coronavirus vaccines against SARS-CoV, MERS-CoV and SARS-CoV-2. D.B.C. is a scientific advisor and holds intellectual property in Atropos Therapeutics, LLC. U.S. declares no competing interests.
References
- Yu J, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 doi: 10.1126/science.abc6284.
- Gao Q, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 doi: 10.1126/science.abc1932.
- Chen W-H, et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement. bioRxiv. 2020 doi: 10.1101/2020.05.15.098079.
- van Doremalen N, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020 doi: 10.1101/2020.05.13.093195.
- Zhu F-C, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)31208-3.
- Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv. 2020 doi: 10.1101/2020.05.13.092619.
- Ghimire TR. The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro versus in vivo paradigm. Springerplus. 2015;4:181. doi: 10.1186/s40064-015-0972-0.
- Millien VO, et al. Airway fibrinogenolysis and the initiation of allergic inflammation. Ann. Am. Thorac. Soc. 2014;11(Suppl. 5):277–283. doi: 10.1513/AnnalsATS.201403-105AW.
- Graham BS, et al. Rapid COVID-19 vaccine development. Science. 2020;368:945–946. doi: 10.1126/science.abb8923.
- Hotez PJ, Corry DB, Bottazzi ME. COVID-19 vaccine design: the Janus face of immune enhancement. Nat. Rev. Immunol. 2020;20:347–348. doi: 10.1038/s41577-020-0323-4.
Source: PubMed